The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The downsizing of health federal agencies comes after Trump threatened to pull the US out of the World Health Organisation ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

From the impact of the new Trump Administration on research and development to advancements in brain health, PBM reform, and ...

For its part, Hims & Hers maintains that the 'Sick of the System' ad – its first for a Super Bowl – "highlights the growing ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency ...

I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...